Sumitomo Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Sumitomo Pharma CEO'su Toru Kimura, Jan2016 tarihinde atandı, in görev süresi 9.33 yıldır. şirketin hisselerinin 0.02% doğrudan sahiptir ve bu hisselerin değeri € 395.39K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 3.9 yıldır.

Anahtar bilgiler

Toru Kimura

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	9.3yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Toru Kimura (64 yo)

9.3yrs

Görev süresi

Mr. Toru Kimura, Ph D., is Representative Director, President & CEO of Sumitomo Pharma Co. Ltd. from June 25, 2024.Mr. Toru serves as Director at Sumitomo Pharma America, Inc. since 2024. He served as Rep...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toru Kimura	Representative Director	9.3yrs	Veri yok	0.020% € 395.4k
Kimihiro Mizuno	Executive Officer of Legal & Compliance; Intellectual Property & Human Resources	less than a year	Veri yok	Veri yok
Koichi Kozuki	E.O. of Corp. Reg. Comp. & Q.A.	2.3yrs	Veri yok	Veri yok
Shigeyuki Nishinaka	Managing Executive Officer	8.1yrs	Veri yok	Veri yok
Isao Shimizu	Exec. Off.	2.3yrs	Veri yok	Veri yok
Kenji Ueno	Executive Officer	2.3yrs	Veri yok	Veri yok
Hideyuki Harada	Mng. Exe. Off. of Supply Chain Div.	4.1yrs	Veri yok	Veri yok
Tsutomu Nakagawa	Managing Executive Officer & Director	2.3yrs	Veri yok	0.00076% € 15.3k
Yumi Sato	Managing Exe. Officer of Research & Dev. Div. Senior VP and Head of Research & Development Division	2.3yrs	Veri yok	Veri yok
Yutaka Wakemi	Executive Officer	no data	Veri yok	Veri yok
Motoyuki Sakai	Rep. Dir.	less than a year	Veri yok	Veri yok
Koji Yamazaki	Exec. Off. of Sales & Mark. Div.	less than a year	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: DPM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toru Kimura	Representative Director	8.9yrs	Veri yok	0.020% € 395.4k
Tsutomu Nakagawa	Managing Executive Officer & Director	less than a year	Veri yok	0.00076% € 15.3k
Motoyuki Sakai	Rep. Dir.	less than a year	Veri yok	Veri yok
Saeko Arai	Independent Outside Director	6.9yrs	Veri yok	Veri yok
Minoru Usui	Independent Outside Director	3.9yrs	Veri yok	Veri yok
Nobuhiro Endo	Independent Outside Director	5.9yrs	Veri yok	Veri yok
Hiroshi Niinuma	Director	less than a year	Veri yok	Veri yok
Takashi Kutsunai	Full-Time Audit & Supervisory Board Member	6.9yrs	Veri yok	0.0065% € 131.7k
Yoshio Iteya	Outside Audit & Supervisory Board Member	6.9yrs	Veri yok	Veri yok
Hisayoshi Kashima	Full-Time Audit & Supervisory Board Member	1.9yrs	Veri yok	0.0035% € 70.9k
Mayumi Mochizuki	Outside Audit & Supervisory Board Member	3.9yrs	Veri yok	Veri yok
Koji Fujimoto	Independent Outside Director	2.9yrs	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DPM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/21 04:09
Gün Sonu Hisse Fiyatı	2025/05/21 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2025/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Sumitomo Pharma Co., Ltd. 21 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Atsushi Seki	Barclays
Ritsuo Watanabe	BofA Global Research
Hidemaru Yamaguchi	Citigroup Global Markets Japan Inc.

Sumitomo Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 26, 2025

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Recent updates

Sumitomo Pharma Co., Ltd. to Report Q1, 2026 Results on Jul 31, 2025

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 26, 2025

Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion.

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025

Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2025

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

Second quarter 2025 earnings released: JP¥121 loss per share (vs JP¥72.68 loss in 2Q 2024)

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings released: EPS: JP¥40.11 (vs JP¥97.83 loss in 1Q 2024)

New minor risk - Share price stability

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings released: JP¥793 loss per share (vs JP¥188 loss in FY 2023)

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: JP¥126 loss per share (vs JP¥28.24 loss in 3Q 2023)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings released: JP¥72.68 loss per share (vs JP¥96.63 loss in 2Q 2023)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

New major risk - Share price stability

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Now 22% undervalued after recent price drop

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

New minor risk - Share price stability

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

Now 28% undervalued after recent price drop

First quarter 2024 earnings released: JP¥97.83 loss per share (vs JP¥78.30 profit in 1Q 2023)

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Full year 2023 earnings released: JP¥188 loss per share (vs JP¥142 profit in FY 2022)

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023

Third quarter 2023 earnings released: JP¥28.24 loss per share (vs JP¥24.94 profit in 3Q 2022)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥96.63 loss per share (vs JP¥79.66 profit in 2Q 2022)

Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. Provides Impairment Loss Guidance for the Second Quarter of the Fiscal Year Ending March 31, 2023

Upcoming dividend of JP¥14.00 per share

Now 20% undervalued

Sumitomo Pharma Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥78.30 (vs JP¥12.09 in 1Q 2022)

Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings released: EPS: JP¥142 (vs JP¥142 in FY 2021)

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Less than half of directors are independent

Upcoming dividend of JP¥14.00 per share

Sumitomo Dainippon Pharma Announces Personnel Changes Including Representative Director and Organizational Realignment

Sumitomo Dainippon Pharma Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Sumitomo Dainippon Pharma Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2022

Now 22% undervalued after recent price drop

Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888

Investor sentiment deteriorated over the past week